Related Experiment Video
Updated: May 2, 2026

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
Can Spasticity Be Prevented? Insights from Preclinical and Clinical Evidence
Radha Korupolu1, Argyrios Stampas1
1Department of Physical Medicine and Rehabilitation, McGovern Medical School, The University of Texas Health Science Center, Houston, TX, USA; TIRR Memorial Hermann Hospital, 1333 Moursund Street, Houston, TX 77030, USA.
Abstract:
Spasticity is a common and disabling consequence of central nervous system injury that evolves progressively over time. Although traditionally viewed as an unavoidable sequela, emerging preclinical and clinical evidence suggests that spasticity may be preventable or mitigated through early, targeted interventions. This article explores the pathophysiology and natural history of spasticity across multiple conditions (stroke, spinal cord injury, traumatic brain injury, cerebral palsy, and multiple sclerosis), reviews early identification strategies, and critically examines preclinical and clinical data supporting spasticity prevention.
More Related Videos
07:20Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
07:12Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis
Published on: February 10, 2026
Related Concept Videos
Spinal Cord Injury ll: Pathophysiology
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Secondary Spinal Cord Injury llI: Pathophysiology